MedTrace Logo

A Trial of SHR-1819 in Healthy Subjects

NCT04561128 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-07-12

No results posted yet for this study

Summary

This is a single center, randomized, double-blind, placebo-controlled, single dose escalation phase 1 study.

Conditions

  • Healthy Volunteers

Interventions

DRUG

SHR-1819

SHR-1819 will be subcutaneously administered with different dose levels

DRUG

Placebo

Placebo will be subcutaneously administered with different dose levels

Sponsors & Collaborators

  • Atridia Pty Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2022-03-07
Completion
2022-03-07

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04561128 on ClinicalTrials.gov